ArticleDiscover oncology2025
Meta_B cells: a computationally identified candidate immunosuppressive driver of gastric cancer metastasis revealed by single-cell analysis and machine learning.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of BTLA in ovarian cancer and its clinical prognostic significance based on multi-omics analysis.Journal of ovarian research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGastric cancer (GC) metastasis remains a major clinical challenge due to insufficient understanding of tumor microenvironment (TME) dynamics. While B cells are implicated in GC progression, their subset-specific roles in metastatic niches are poorly defined.
methodsWe analyzed gastric cancer (GC) single-cell RNA-seq data from the GEO database (GSE163558), complemented by bulk RNA-seq analysis of TCGA-STAD cohorts. Meta_B cells were identified through Seurat clustering and validated in colorectal cancer metastases (GSE166555). And we constructed a prognostic model via hdWGCNA and LASSO-Cox regression. Functional analyses included GSEA, pseudotime trajectory (Monocle2) and cell-cell communication (CellChat).
resultsWe identified meta_B cells, a metastasis-enriched B cell subset, characterized by CLEC2B/YBX3 overexpression. Functional analyses suggested a potential immunosuppressive role associated with computational inference of BTLA-TNFRSF14 pathway activation, correlating with interactions with macrophages and other immune cells. A machine learning-derived 10-gene prognostic model effectively stratified high-risk patients with stromal-rich tumor microenvironments and predicted potential enhanced chemosensitivity to axitinib, dasatinib, olaparib, rapamycin, and ribociclib.
conclusionsMeta_B cells may represent a novel B cell subset computationally associated with immunosuppression and GC metastasis potentially mediated by the BTLA axis. Our integrative transcriptomic framework provides hypothesis-generating insights into metastatic TME remodeling and a clinically actionable tool for prognostic prediction. Targeting meta_B cells can be explored as a strategy to potentially overcome immunotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.